nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

21.11.2019 | short review

ASCO 2019—Personal highlights on adjuvant breast cancer: (neo-)adjuvant therapy of HER2-negative HR-positive BC

verfasst von: Prof. Semir Beslija, MD, PhD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Summary

This article intends to summarize personal highlights from the 2019 ASCO (American Society of Clinical Oncology) Annual meeting. The article does not aim to offer a comprehensive summary of the 1642 abstracts presented, but rather aims to highlight the abstracts that are the most relevant for the neo/adjuvant therapy of the HER2-negative, HR-positive breast cancer. By doing so, the article generates discussion on the practical implications, while portraying the rapidly changing landscape of the use of personalized treatment of early breast cancer in patients with HER2-negative, HR-positive disease.

Vorheriger Artikel Targeted therapy in lung cancer—ASCO 2019 update

Nächster Artikel ASCO 2019: highlights in HER2-positive metastatic breast cancer

Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111–21.CrossRef

Sparano JA, Gray RJ, Ravdin PM, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019;380:2395–405.CrossRef

Sparano JA, Gray RJ, Makower DF, et al. Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx. In: Program and abstracts of the 2019 American Society of Clinical Oncology annual meeting. May 31–June 4, 2019; Chicago, Illinois. 2019. Abstract 503.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCB). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.CrossRef

Mamounas EP, Jeong JH, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B‑33 trial. J Clin Oncol. 2008;26:1965–71.CrossRef

Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793–802.CrossRef

Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262–71.CrossRef

Jakesz R, Greil R, Gnant M, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst. 2007;99:1845–53.CrossRef

Del Mastro L, Mansutti M, Bisagni G, et al. Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: a randomized, phase III study of Gruppo Italiano Mammella (GIM). In: Program and abstracts of the 2019 American Society of Clinical Oncology annual meeting. May 31–June 4, 2019; Chicago, Illinois. 2019. Abstract 504.

10.

Gnant M, Steger G, Greil R, et al. A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy: results from 3,484 postmenopausal women in the ABCSG-16 trial. In: Program and abstracts of the 2017 San Antonio Breast Cancer Symposium. December 5–9, 2017; San Antonio, Texas. 2017. Abstract GS3-01.

11.

Gray RG, Rea D, Handley K, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. In: Program and abstracts of the 2013 American Society of Clinical Oncology annual meeting. May 31–June 4, 2013; Chicago, Illinois. 2013. Abstract 5.

12.

Sgroi DC, Carney E, Zarrella E, et al. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst. 2013;14:1036–42.CrossRef

13.

Zhang Y, Schnabel CA, Schroeder BE, et al. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. Clin Cancer Res. 2013;19:4196–205.CrossRef

14.

Bartlett J, Sgroi D, Treuner K, et al. Trans-aTTom: Breast Cancer Index for prediction of endocrine benefit and late distant recurrence (DR) in patients with HR+ breast cancer treated in the adjuvant tamoxifen—to offer more? (aTTom) trial. In: Program and abstracts of the 2019 American Society of Clinical Oncology annual meeting. May 31–June 4, 2019; Chicago, Illinois. 2019. Abstract 505.

Titel: ASCO 2019—Personal highlights on adjuvant breast cancer: (neo-)adjuvant therapy of HER2-negative HR-positive BC
verfasst von: Prof. Semir Beslija, MD, PhD
Publikationsdatum: 21.11.2019
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-019-00546-3

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

Optimizing care for geriatric cancer patients: the greatest challenge in medical oncology?

Neoadjuvant therapy in urothelial cancer

Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer

HPV-associated cancers

An update from the 2019 ASCO Annual Meeting

Giant leiomyoma of the renal capsule: CT and MR imaging features with pathologic correlations